FDA Approval For Empaveli Marks Key Milestone In Apellis' Rare Disease Portfolio

benzinga.com/news/fda/25/07/46696495/fda-approval-for-empaveli-marks-key-milestone-in-apellis-rare-disease-portfolio

The U.S. Food and Drug Administration approved on Monday Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Empaveli (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and…

This story appeared on benzinga.com, 2025-07-29 16:12:25.
The Entire Business World on a Single Page. Free to Use →